Pharmacists want full script powers
GPs will have to wait for clarification on their use of cox-2 inhibitors after the European Medicines Agency stalled from giving advice.
The EMEA announced its review of cox-2s in Oct-
ober, following the withdrawal of rofecoxib after a long-
term study showed increased risk of heart attack and stroke.
Its expert committee this week requested more analysis of data from two new long-term trials with celecoxib.
One showed an increased risk of heart attack and stroke after taking the drug but the other showed no increased risk.